Baird Maintains Outperform on Intercept Pharma, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Intercept Pharma (NASDAQ:ICPT) but lowers the price target from $35 to $18.
May 22, 2023 | 11:24 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst lowers Intercept Pharma's price target from $35 to $18 while maintaining an Outperform rating.
The news of Baird analyst Brian Skorney maintaining an Outperform rating on Intercept Pharma (NASDAQ:ICPT) is positive for the company. However, the lowering of the price target from $35 to $18 indicates a reduced growth expectation, which may offset the positive sentiment. This results in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100